H.C. Wainwright analyst Douglas Tsao lowered the firm’s price target on Aeon Biopharma to $5 from $6 and keeps a Buy rating on the shares. The analyst believes the outcome of the biosimilar meeting should clarify the development path for ABP-450 and should attract investor interest to provide the program’s needed funding.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AEON: